NeuroOne Medical Technologies Corporation reported fiscal third quarter 2026 results ending June 30, 2026. Product revenue increased 16% year-over-year to $2.0 million, while product gross margins expanded to a record 59.9%. The company received $2.7 million in new product orders, growing its backlog to $1.7 million. Total operating expenses rose to $3.6 million, resulting in a net loss of $2.0 million, or ($0.23) per basic share. Cash and cash equivalents decreased to $2.0 million from $6.6 million at the start of the fiscal year. The company raised an additional $1.0 million via its ATM program subsequent to quarter-end. NeuroOne operates in the medical technology industry, developing minimally invasive surgical diagnosis and treatment solutions for neurological disorders.

NeuroOne Medical Technologies Corporation filed an updated Prospectus Supplement to offer and sell up to $13.4 million of common stock through an at-the-market offering program with JonesTrading Institutional Services LLC. The company is a developer of medical technology solutions for neurological and neurological-related disorders.